Proactiveinvestors United Kingdom Amphion Innovations

<pre class="cake-debug">
<a href='javascript:void(0);' onclick='document.getElementById("CakeStackTrace1").style.display = (document.getElementById("CakeStackTrace1").style.display == "none" ? "" : "none")'><b>Warning</b> (2)</a>: mssql_query() [<a href='http://php.net/function.mssql-query'>function.mssql-query</a>]: Some character(s) could not be converted into client's character set.  Unconverted bytes were changed to question marks ('?') (severity 4) [<b>CORE/cake/libs/model/datasources/dbo/dbo_mssql.php</b>, line <b>181</b>]
</pre>
<div id="CakeStackTrace1" class="cake-stack-trace" style="display: none;"><a href='javascript:void(0);' onclick='document.getElementById("CakeErrorCode1").style.display = (document.getElementById("CakeErrorCode1").style.display == "none" ? "" : "none")'>Code</a> | <a href='javascript:void(0);' onclick='document.getElementById("CakeErrorContext1").style.display = (document.getElementById("CakeErrorContext1").style.display == "none" ? "" : "none")'>Context</a><pre id="CakeErrorContext1" class="cake-context" style="display: none;">$sql	=	"SELECT  TOP 90 [Brokerpress].[comment] AS [Brokerpress__0], CAST(Brokerpress.date AS datetime) AS [date] FROM [brokerpress] AS [Brokerpress]   WHERE [Brokerpress].[epic] = &#039;AMP&#039;   ORDER BY [Brokerpress].[date] DESC"</pre><pre>mssql_query - [internal], line ??
DboMssql::_execute() - CORE/cake/libs/model/datasources/dbo/dbo_mssql.php, line 181
DboSource::execute() - CORE/cake/libs/model/datasources/dbo_source.php, line 190
DboSource::fetchAll() - CORE/cake/libs/model/datasources/dbo_source.php, line 338
DboSource::read() - CORE/cake/libs/model/datasources/dbo_source.php, line 655
DboMssql::read() - CORE/cake/libs/model/datasources/dbo/dbo_mssql.php, line 643
Model::find() - CORE/cake/libs/model/model.php, line 2031
Controller::paginate() - CORE/cake/libs/controller/controller.php, line 1095
AppController::paginate() - APP/app_controller.php, line 272
AppController::fetch() - APP/app_controller.php, line 320
RssController::all_news() - APP/plugins/profiles/controllers/rss_controller.php, line 128
Object::dispatchMethod() - CORE/cake/libs/object.php, line 116
Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 227
Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194
[main] - APP/webroot/index.php, line 91</pre></div>
<pre class="cake-debug">
<a href='javascript:void(0);' onclick='document.getElementById("CakeStackTrace2").style.display = (document.getElementById("CakeStackTrace2").style.display == "none" ? "" : "none")'><b>Warning</b> (2)</a>: Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [<b>APP/views/layouts/rss.ctp</b>, line <b>2</b>]
</pre>
<div id="CakeStackTrace2" class="cake-stack-trace" style="display: none;"><a href='javascript:void(0);' onclick='document.getElementById("CakeErrorCode2").style.display = (document.getElementById("CakeErrorCode2").style.display == "none" ? "" : "none")'>Code</a> | <a href='javascript:void(0);' onclick='document.getElementById("CakeErrorContext2").style.display = (document.getElementById("CakeErrorContext2").style.display == "none" ? "" : "none")'>Context</a><pre id="CakeErrorContext2" class="cake-context" style="display: none;">$___viewFn	=	"/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView	=	array(
	"facebookSession" => 0,
	"searchHeader_limit" => null,
	"company" => array(
	"Company" => array()
),
	"brokerpresses" => array(
	array(),
	array()
),
	"items" => array(
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array()
),
	"title_for_layout" => "Rss",
	"content_for_layout" => "&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
",
	"scripts_for_layout" => "",
	"cakeDebug" => "",
	"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
	"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
	"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
	"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
	"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
	"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
	"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
	"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
	"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers	=	false
$cached	=	true
$loadedHelpers	=	array()
$facebookSession	=	0
$searchHeader_limit	=	null
$company	=	array(
	"Company" => array(
	"id" => "89",
	"epic" => "AMP",
	"name" => "Amphion Innovations",
	"is_sponsor" => "1",
	"international_sponsorship" => "NA, UK"
)
)
$brokerpresses	=	array(
	array(
	"Brokerpress" => array()
),
	array(
	"Brokerpress" => array()
)
)
$items	=	array(
	array(
	"id" => "42532",
	"title" => "News - Amphion Innovations gets US$500,000 loan from chairman",
	"pubdate" => "2012-05-09 09:36:00",
	"seftitle" => "amphion-innovations-gets-us500000-loan-from-chairman-42532.html",
	"description" => "&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html"
),
	array(
	"id" => "120509amp9601c",
	"title" => "RNS press release - Funding update",
	"pubdate" => "2012-05-09 09:20:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/"
),
	array(
	"id" => "42192",
	"title" => "News - Amphion Innovations’ partner Axcess reaches milestone in patent case",
	"pubdate" => "2012-05-01 08:20:00",
	"seftitle" => "amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html"
),
	array(
	"id" => "120501amp4213c",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-05-01 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/"
),
	array(
	"id" => "40829",
	"title" => "News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility",
	"pubdate" => "2012-03-28 08:19:00",
	"seftitle" => "amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html"
),
	array(
	"id" => "120328amp2148a",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-03-28 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/"
),
	array(
	"id" => "120228amp2246y",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2012-02-28 07:01:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/"
),
	array(
	"id" => "39373",
	"title" => "News - Amphion Innovations secures additional US$500,000 loan from chairman",
	"pubdate" => "2012-02-24 07:15:00",
	"seftitle" => "amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html"
),
	array(
	"id" => "120223amp0271y",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-23 16:37:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/"
),
	array(
	"id" => "38573",
	"title" => "News - Amphion Innovations secures US$500,000 loan from chairman",
	"pubdate" => "2012-02-03 15:52:00",
	"seftitle" => "amphion-innovations-secures-us500000-loan-from-chairman-38573.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html"
),
	array(
	"id" => "120203amp7979w",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-03 15:24:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/"
),
	array(
	"id" => "38505",
	"title" => "News - Amphion Innovations shares rise as DataTern patents are reinforced",
	"pubdate" => "2012-02-02 10:39:00",
	"seftitle" => "amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html",
	"description" => "&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html"
),
	array(
	"id" => "120202amp6339w",
	"title" => "RNS press release - Patent Approval",
	"pubdate" => "2012-02-02 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/"
),
	array(
	"id" => "111230amp7695u",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2011-12-30 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/"
),
	array(
	"id" => "37123",
	"title" => "News - Amphion Innovations is significantly undervalued against its NAV, says broker",
	"pubdate" => "2011-12-19 13:40:00",
	"seftitle" => "amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html"
),
	array(
	"id" => "111206amp4225t",
	"title" => "RNS press release - Director/PDMR Shareholding",
	"pubdate" => "2011-12-06 09:10:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/"
),
	array(
	"id" => "35883",
	"title" => "News - Amphion Innovations subsidiary DataTern files patent infringement suits in US ",
	"pubdate" => "2011-11-21 10:18:00",
	"seftitle" => "amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html"
),
	array(
	"id" => "111121amp4373s",
	"title" => "RNS press release - New Suits Filed and New Debt Facilites",
	"pubdate" => "2011-11-21 08:43:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/"
),
	array(
	"id" => "33728",
	"title" => "News - Amphion Innovations moves into the black during first half",
	"pubdate" => "2011-09-29 07:43:00",
	"seftitle" => "amphion-innovations-moves-into-the-black-during-first-half-33728.html",
	"description" => "&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html"
),
	array(
	"id" => "110929amp1345p",
	"title" => "RNS press release - Half Yearly Report",
	"pubdate" => "2011-09-29 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/"
)
)
$title_for_layout	=	"Rss"
$content_for_layout	=	"&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
"
$scripts_for_layout	=	""
$cakeDebug	=	""
$javascript	=	JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html	=	HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time	=	TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form	=	FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai	=	PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session	=	SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile	=	ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator	=	PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax	=	AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object</pre><pre>header - [internal], line ??
include - APP/views/layouts/rss.ctp, line 2
View::_render() - CORE/cake/libs/view/view.php, line 667
View::renderLayout() - CORE/cake/libs/view/view.php, line 454
View::render() - CORE/cake/libs/view/view.php, line 388
Controller::render() - CORE/cake/libs/controller/controller.php, line 806
Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230
Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194
[main] - APP/webroot/index.php, line 91</pre></div>
<pre class="cake-debug">
<a href='javascript:void(0);' onclick='document.getElementById("CakeStackTrace3").style.display = (document.getElementById("CakeStackTrace3").style.display == "none" ? "" : "none")'><b>Warning</b> (2)</a>: Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [<b>APP/views/layouts/rss.ctp</b>, line <b>3</b>]
</pre>
<div id="CakeStackTrace3" class="cake-stack-trace" style="display: none;"><a href='javascript:void(0);' onclick='document.getElementById("CakeErrorCode3").style.display = (document.getElementById("CakeErrorCode3").style.display == "none" ? "" : "none")'>Code</a> | <a href='javascript:void(0);' onclick='document.getElementById("CakeErrorContext3").style.display = (document.getElementById("CakeErrorContext3").style.display == "none" ? "" : "none")'>Context</a><pre id="CakeErrorContext3" class="cake-context" style="display: none;">$___viewFn	=	"/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView	=	array(
	"facebookSession" => 0,
	"searchHeader_limit" => null,
	"company" => array(
	"Company" => array()
),
	"brokerpresses" => array(
	array(),
	array()
),
	"items" => array(
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array()
),
	"title_for_layout" => "Rss",
	"content_for_layout" => "&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
",
	"scripts_for_layout" => "",
	"cakeDebug" => "",
	"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
	"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
	"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
	"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
	"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
	"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
	"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
	"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
	"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers	=	false
$cached	=	true
$loadedHelpers	=	array()
$facebookSession	=	0
$searchHeader_limit	=	null
$company	=	array(
	"Company" => array(
	"id" => "89",
	"epic" => "AMP",
	"name" => "Amphion Innovations",
	"is_sponsor" => "1",
	"international_sponsorship" => "NA, UK"
)
)
$brokerpresses	=	array(
	array(
	"Brokerpress" => array()
),
	array(
	"Brokerpress" => array()
)
)
$items	=	array(
	array(
	"id" => "42532",
	"title" => "News - Amphion Innovations gets US$500,000 loan from chairman",
	"pubdate" => "2012-05-09 09:36:00",
	"seftitle" => "amphion-innovations-gets-us500000-loan-from-chairman-42532.html",
	"description" => "&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html"
),
	array(
	"id" => "120509amp9601c",
	"title" => "RNS press release - Funding update",
	"pubdate" => "2012-05-09 09:20:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/"
),
	array(
	"id" => "42192",
	"title" => "News - Amphion Innovations’ partner Axcess reaches milestone in patent case",
	"pubdate" => "2012-05-01 08:20:00",
	"seftitle" => "amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html"
),
	array(
	"id" => "120501amp4213c",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-05-01 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/"
),
	array(
	"id" => "40829",
	"title" => "News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility",
	"pubdate" => "2012-03-28 08:19:00",
	"seftitle" => "amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html"
),
	array(
	"id" => "120328amp2148a",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-03-28 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/"
),
	array(
	"id" => "120228amp2246y",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2012-02-28 07:01:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/"
),
	array(
	"id" => "39373",
	"title" => "News - Amphion Innovations secures additional US$500,000 loan from chairman",
	"pubdate" => "2012-02-24 07:15:00",
	"seftitle" => "amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html"
),
	array(
	"id" => "120223amp0271y",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-23 16:37:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/"
),
	array(
	"id" => "38573",
	"title" => "News - Amphion Innovations secures US$500,000 loan from chairman",
	"pubdate" => "2012-02-03 15:52:00",
	"seftitle" => "amphion-innovations-secures-us500000-loan-from-chairman-38573.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html"
),
	array(
	"id" => "120203amp7979w",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-03 15:24:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/"
),
	array(
	"id" => "38505",
	"title" => "News - Amphion Innovations shares rise as DataTern patents are reinforced",
	"pubdate" => "2012-02-02 10:39:00",
	"seftitle" => "amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html",
	"description" => "&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html"
),
	array(
	"id" => "120202amp6339w",
	"title" => "RNS press release - Patent Approval",
	"pubdate" => "2012-02-02 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/"
),
	array(
	"id" => "111230amp7695u",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2011-12-30 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/"
),
	array(
	"id" => "37123",
	"title" => "News - Amphion Innovations is significantly undervalued against its NAV, says broker",
	"pubdate" => "2011-12-19 13:40:00",
	"seftitle" => "amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html"
),
	array(
	"id" => "111206amp4225t",
	"title" => "RNS press release - Director/PDMR Shareholding",
	"pubdate" => "2011-12-06 09:10:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/"
),
	array(
	"id" => "35883",
	"title" => "News - Amphion Innovations subsidiary DataTern files patent infringement suits in US ",
	"pubdate" => "2011-11-21 10:18:00",
	"seftitle" => "amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html"
),
	array(
	"id" => "111121amp4373s",
	"title" => "RNS press release - New Suits Filed and New Debt Facilites",
	"pubdate" => "2011-11-21 08:43:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/"
),
	array(
	"id" => "33728",
	"title" => "News - Amphion Innovations moves into the black during first half",
	"pubdate" => "2011-09-29 07:43:00",
	"seftitle" => "amphion-innovations-moves-into-the-black-during-first-half-33728.html",
	"description" => "&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html"
),
	array(
	"id" => "110929amp1345p",
	"title" => "RNS press release - Half Yearly Report",
	"pubdate" => "2011-09-29 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/"
)
)
$title_for_layout	=	"Rss"
$content_for_layout	=	"&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
"
$scripts_for_layout	=	""
$cakeDebug	=	""
$javascript	=	JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html	=	HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time	=	TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form	=	FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai	=	PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session	=	SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile	=	ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator	=	PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax	=	AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object</pre><pre>header - [internal], line ??
include - APP/views/layouts/rss.ctp, line 3
View::_render() - CORE/cake/libs/view/view.php, line 667
View::renderLayout() - CORE/cake/libs/view/view.php, line 454
View::render() - CORE/cake/libs/view/view.php, line 388
Controller::render() - CORE/cake/libs/controller/controller.php, line 806
Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230
Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194
[main] - APP/webroot/index.php, line 91</pre></div>
<pre class="cake-debug">
<a href='javascript:void(0);' onclick='document.getElementById("CakeStackTrace4").style.display = (document.getElementById("CakeStackTrace4").style.display == "none" ? "" : "none")'><b>Warning</b> (2)</a>: Cannot modify header information - headers already sent by (output started at /home/paiuk/public_html/cake/basics.php:111) [<b>APP/views/layouts/rss.ctp</b>, line <b>4</b>]
</pre>
<div id="CakeStackTrace4" class="cake-stack-trace" style="display: none;"><a href='javascript:void(0);' onclick='document.getElementById("CakeErrorCode4").style.display = (document.getElementById("CakeErrorCode4").style.display == "none" ? "" : "none")'>Code</a> | <a href='javascript:void(0);' onclick='document.getElementById("CakeErrorContext4").style.display = (document.getElementById("CakeErrorContext4").style.display == "none" ? "" : "none")'>Context</a><pre id="CakeErrorContext4" class="cake-context" style="display: none;">$___viewFn	=	"/home/paiuk/public_html/app/views/layouts/rss.ctp"
$___dataForView	=	array(
	"facebookSession" => 0,
	"searchHeader_limit" => null,
	"company" => array(
	"Company" => array()
),
	"brokerpresses" => array(
	array(),
	array()
),
	"items" => array(
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array(),
	array()
),
	"title_for_layout" => "Rss",
	"content_for_layout" => "&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
",
	"scripts_for_layout" => "",
	"cakeDebug" => "",
	"javascript" => JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL,
	"html" => HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL,
	"time" => TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL,
	"form" => FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object,
	"pai" => PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object,
	"session" => SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles",
	"profile" => ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object,
	"paginator" => PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object,
	"ajax" => AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object
)
$loadHelpers	=	false
$cached	=	true
$loadedHelpers	=	array()
$facebookSession	=	0
$searchHeader_limit	=	null
$company	=	array(
	"Company" => array(
	"id" => "89",
	"epic" => "AMP",
	"name" => "Amphion Innovations",
	"is_sponsor" => "1",
	"international_sponsorship" => "NA, UK"
)
)
$brokerpresses	=	array(
	array(
	"Brokerpress" => array()
),
	array(
	"Brokerpress" => array()
)
)
$items	=	array(
	array(
	"id" => "42532",
	"title" => "News - Amphion Innovations gets US$500,000 loan from chairman",
	"pubdate" => "2012-05-09 09:36:00",
	"seftitle" => "amphion-innovations-gets-us500000-loan-from-chairman-42532.html",
	"description" => "&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html"
),
	array(
	"id" => "120509amp9601c",
	"title" => "RNS press release - Funding update",
	"pubdate" => "2012-05-09 09:20:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/"
),
	array(
	"id" => "42192",
	"title" => "News - Amphion Innovations’ partner Axcess reaches milestone in patent case",
	"pubdate" => "2012-05-01 08:20:00",
	"seftitle" => "amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html"
),
	array(
	"id" => "120501amp4213c",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-05-01 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/"
),
	array(
	"id" => "40829",
	"title" => "News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility",
	"pubdate" => "2012-03-28 08:19:00",
	"seftitle" => "amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html"
),
	array(
	"id" => "120328amp2148a",
	"title" => "RNS press release - Partner Company Update",
	"pubdate" => "2012-03-28 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/"
),
	array(
	"id" => "120228amp2246y",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2012-02-28 07:01:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/"
),
	array(
	"id" => "39373",
	"title" => "News - Amphion Innovations secures additional US$500,000 loan from chairman",
	"pubdate" => "2012-02-24 07:15:00",
	"seftitle" => "amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html"
),
	array(
	"id" => "120223amp0271y",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-23 16:37:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/"
),
	array(
	"id" => "38573",
	"title" => "News - Amphion Innovations secures US$500,000 loan from chairman",
	"pubdate" => "2012-02-03 15:52:00",
	"seftitle" => "amphion-innovations-secures-us500000-loan-from-chairman-38573.html",
	"description" => "&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html"
),
	array(
	"id" => "120203amp7979w",
	"title" => "RNS press release - Funding Update",
	"pubdate" => "2012-02-03 15:24:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/"
),
	array(
	"id" => "38505",
	"title" => "News - Amphion Innovations shares rise as DataTern patents are reinforced",
	"pubdate" => "2012-02-02 10:39:00",
	"seftitle" => "amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html",
	"description" => "&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html"
),
	array(
	"id" => "120202amp6339w",
	"title" => "RNS press release - Patent Approval",
	"pubdate" => "2012-02-02 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/"
),
	array(
	"id" => "111230amp7695u",
	"title" => "RNS press release - Director Dealings",
	"pubdate" => "2011-12-30 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/"
),
	array(
	"id" => "37123",
	"title" => "News - Amphion Innovations is significantly undervalued against its NAV, says broker",
	"pubdate" => "2011-12-19 13:40:00",
	"seftitle" => "amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html"
),
	array(
	"id" => "111206amp4225t",
	"title" => "RNS press release - Director/PDMR Shareholding",
	"pubdate" => "2011-12-06 09:10:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/"
),
	array(
	"id" => "35883",
	"title" => "News - Amphion Innovations subsidiary DataTern files patent infringement suits in US ",
	"pubdate" => "2011-11-21 10:18:00",
	"seftitle" => "amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html",
	"description" => "&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html"
),
	array(
	"id" => "111121amp4373s",
	"title" => "RNS press release - New Suits Filed and New Debt Facilites",
	"pubdate" => "2011-11-21 08:43:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/"
),
	array(
	"id" => "33728",
	"title" => "News - Amphion Innovations moves into the black during first half",
	"pubdate" => "2011-09-29 07:43:00",
	"seftitle" => "amphion-innovations-moves-into-the-black-during-first-half-33728.html",
	"description" => "&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;",
	"link" => "http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html"
),
	array(
	"id" => "110929amp1345p",
	"title" => "RNS press release - Half Yearly Report",
	"pubdate" => "2011-09-29 07:00:00",
	"seftitle" => "",
	"description" => "",
	"link" => "http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/"
)
)
$title_for_layout	=	"Rss"
$content_for_layout	=	"&lt;channel&gt;
	&lt;title&gt;Proactiveinvestors United Kingdom Amphion Innovations&lt;/title&gt;
	&lt;link&gt;http://www.proactiveinvestors.co.uk&lt;/link&gt;
	&lt;description&gt;Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            &lt;/description&gt;
	&lt;language&gt;en&lt;/language&gt;
	&lt;pubDate&gt;Wed, 16 May 2012 17:50:10 +0100&lt;/pubDate&gt;
	&lt;docs&gt;http://blogs.law.harvard.edu/tech/rss&lt;/docs&gt;
	&lt;generator&gt;Genera CMS&lt;/generator&gt;
	&lt;managingEditor&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/managingEditor&gt;
	&lt;webMaster&gt;action@proactiveinvestors.com (Proactiveinvestors)&lt;/webMaster&gt;
	&lt;atom:link href=&quot;http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news&quot; rel=&quot;self&quot; type=&quot;application/rss+xml&quot; /&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;
&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.&lt;/p&gt;
&lt;p&gt;The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.&lt;/p&gt;
&lt;p&gt;The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.&lt;/p&gt;
&lt;p&gt;On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&amp;nbsp;&lt;/p&gt;
&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:36:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 09 May 2012 09:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&amp;rsquo;s partner companies.&lt;/p&gt;
&lt;p&gt;A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&amp;nbsp;&lt;/p&gt;
&lt;p&gt;It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.&lt;/p&gt;
&lt;p&gt;Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.&lt;/p&gt;
&lt;p&gt;The judge essentially upheld the validity of Axcess&amp;rsquo; claim and set down the case for trial on November 5.&lt;/p&gt;
&lt;p&gt;Amphion described the ruling can as &amp;ldquo;favourable&amp;rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &amp;nbsp;&lt;/p&gt;
&lt;p&gt;Axcess chief executive Allan Griebenow said: &quot;Having reached this important milestone, we now look forward to the trial in early November. &amp;nbsp;We encourage interested parties to read the order.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio.&quot;&lt;/p&gt;
&lt;p&gt;Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.&lt;/p&gt;
&lt;p&gt;A copy of the court&#039;s ruling can be downloaded from &lt;a href=&quot;http://www.proactiveinvestors.co.uk/www.axcessinc.com&quot; target=&quot;_blank&quot;&gt;www.axcessinc.com&lt;/a&gt;.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 08:20:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 01 May 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.&lt;br /&gt;&lt;br /&gt;The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.&lt;/p&gt;
&lt;p&gt;Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.&lt;br /&gt;&lt;br /&gt;Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled &quot;High Sensitivity Demodulator For A Radio Tag And Method&quot; and the other &quot;Dual Frequency Radio Tag For A Radio Frequency Identification System&quot;.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.&lt;br /&gt;&lt;br /&gt;The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. &lt;br /&gt;&lt;br /&gt;Axcess chief executive Allan Griebenow said: &amp;ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations.&quot;&lt;br /&gt;&amp;nbsp;&lt;br /&gt;Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 08:19:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Partner Company Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Wed, 28 Mar 2012 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 28 Feb 2012 07:01:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.&lt;br /&gt;&lt;br /&gt;The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.&lt;br /&gt;&lt;br /&gt;Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 24 Feb 2012 07:15:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 23 Feb 2012 16:37:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.&lt;br /&gt;&lt;br /&gt;Macaleer holds a 17.37 per cent stake in the company.&lt;br /&gt;&lt;br /&gt;The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.&lt;br /&gt;&lt;br /&gt;The chairman&amp;rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.&lt;br /&gt;&lt;br /&gt;Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. &lt;br /&gt;&lt;br /&gt;This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company&#039;s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:52:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Funding Update ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 03 Feb 2012 15:24:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&amp;nbsp;United States Patent and Trademark Office.&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 10:39:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Patent Approval ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 02 Feb 2012 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director Dealings ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Fri, 30 Dec 2011 07:00:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.&lt;br /&gt;&lt;br /&gt;The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a &#039;buy&#039; targeting a price of 10 pence (current price: 4 pence a share).&lt;br /&gt;&lt;br /&gt;&quot;In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV,&quot; said Mitchell.&lt;br /&gt;&lt;br /&gt;However, the analyst conceded that in the light of wider market conditions, that discount was justified.&lt;br /&gt;&lt;br /&gt;But he added: &quot;However, with the DataTern business effectively acting as an &amp;lsquo;engine&amp;rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. &lt;br /&gt;&lt;br /&gt;&quot;Instead, we believe a discount of around 30 per cent is more justified,&quot; he said, adding that the broker&#039;s own target price had been worked out at 10 pence.&lt;br /&gt;&lt;br /&gt;Since floating in 2005, the firm&#039;s strategy has been to build high-potential companies with innovative, proprietary, and proven technology. &lt;br /&gt;&lt;br /&gt;This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.&lt;br /&gt;&lt;br /&gt;&quot;While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues,&quot; said Dr Mitchell.&lt;br /&gt;&lt;br /&gt;The analyst added that DataTern&#039;s ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.&lt;br /&gt;&lt;br /&gt;&quot;Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.&lt;br /&gt;&lt;br /&gt;&quot;We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term,&quot; concluded the analyst.&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 19 Dec 2011 13:40:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Director/PDMR Shareholding ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Tue, 06 Dec 2011 09:10:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;Technology commercialisation firm &lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;Amphion Innovations&lt;/a&gt; (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot; class=&quot;companyPopupTrigger&quot; rel=&quot;89&quot;&gt;LON:AMP&lt;/a&gt;) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.&lt;br /&gt;&lt;br /&gt;The suits were filed in the District Court of Massachusetts, asserting infringement of the &#039;502 patent.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The &#039;502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&amp;nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. &lt;br /&gt;&lt;br /&gt;DataTern chief executive officer John Caruso said: &quot;Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&amp;nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission.&quot;&lt;br /&gt;&lt;br /&gt;DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&amp;nbsp;&amp;nbsp; DataTern is represented by McCarter &amp;amp; English LLP in Boston.&lt;br /&gt;&lt;br /&gt;Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&amp;nbsp; &lt;br /&gt;&lt;br /&gt;Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.&lt;br /&gt;&lt;br /&gt;Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.&lt;br /&gt;&lt;br /&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt; ]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 10:18:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Mon, 21 Nov 2011 08:43:00 +0000&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[News - Amphion Innovations moves into the black during first half ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;Interim results from Amphion Innovations (&lt;a href=&quot;http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html&quot;&gt;&lt;a href=&quot;/companies/overview/89/amphion-innovations-0089.html&quot;&gt;LON:AMP&lt;/a&gt;&lt;/a&gt;) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.&lt;/p&gt;
&lt;p&gt;The firm&amp;rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &amp;pound;270,403 (H1 2010: &amp;pound;2.7 million).&lt;/p&gt;
&lt;p&gt;Amphion&amp;rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp;amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &amp;nbsp;DataTern has taken &amp;ldquo;concrete steps&amp;rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.&lt;/p&gt;
&lt;p&gt;Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&amp;rsquo;s &amp;lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&amp;rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.&lt;/p&gt;
&lt;p&gt;DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).&lt;/p&gt;
&lt;p&gt;Among Amphion&amp;rsquo;s &amp;lsquo;Partner Companies&amp;rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &amp;ldquo;important and exciting&amp;rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.&lt;/p&gt;
&lt;p&gt;&amp;ldquo;We are pleased to be reporting an improved set of results for the company,&amp;rdquo; said Richard Morgan, Amphion&amp;rsquo;s chairman and chief executive officer. &amp;ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &amp;nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion&#039;s results, with a positive impact on Amphion&#039;s financial condition and its ability to fund and grow its Partner Companies.&amp;rdquo;&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:43:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html&lt;/guid&gt;
		&lt;/item&gt;
		&lt;item&gt;
			&lt;title&gt;&lt;![CDATA[RNS press release - Half Yearly Report ]]&gt;&lt;/title&gt;
			&lt;link&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/link&gt;
			&lt;description&gt;&lt;![CDATA[]]&gt;&lt;/description&gt;
			&lt;pubDate&gt;Thu, 29 Sep 2011 07:00:00 +0100&lt;/pubDate&gt;
			&lt;guid&gt;http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/&lt;/guid&gt;
		&lt;/item&gt;
&lt;/channel&gt;
"
$scripts_for_layout	=	""
$cakeDebug	=	""
$javascript	=	JavascriptHelper
JavascriptHelper::$useNative = true
JavascriptHelper::$enabled = true
JavascriptHelper::$safe = false
JavascriptHelper::$tags = array
JavascriptHelper::$_blockOptions = array
JavascriptHelper::$_cachedEvents = array
JavascriptHelper::$_cacheEvents = false
JavascriptHelper::$_cacheToFile = false
JavascriptHelper::$_cacheAll = false
JavascriptHelper::$_rules = array
JavascriptHelper::$__scriptBuffer = NULL
JavascriptHelper::$helpers = NULL
JavascriptHelper::$base = ""
JavascriptHelper::$webroot = "/"
JavascriptHelper::$themeWeb = NULL
JavascriptHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
JavascriptHelper::$params = array
JavascriptHelper::$action = "all_news"
JavascriptHelper::$plugin = "profiles"
JavascriptHelper::$data = NULL
JavascriptHelper::$namedArgs = NULL
JavascriptHelper::$argSeparator = NULL
JavascriptHelper::$validationErrors = NULL
JavascriptHelper::$__tainted = NULL
JavascriptHelper::$__cleaned = NULL
JavascriptHelper::$_log = NULL
$html	=	HtmlHelper
HtmlHelper::$tags = array
HtmlHelper::$base = ""
HtmlHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
HtmlHelper::$params = array
HtmlHelper::$action = "all_news"
HtmlHelper::$data = NULL
HtmlHelper::$_crumbs = array
HtmlHelper::$__docTypes = array
HtmlHelper::$helpers = NULL
HtmlHelper::$webroot = "/"
HtmlHelper::$themeWeb = NULL
HtmlHelper::$plugin = "profiles"
HtmlHelper::$namedArgs = NULL
HtmlHelper::$argSeparator = NULL
HtmlHelper::$validationErrors = NULL
HtmlHelper::$__tainted = NULL
HtmlHelper::$__cleaned = NULL
HtmlHelper::$_log = NULL
$time	=	TimeHelper
TimeHelper::$helpers = NULL
TimeHelper::$base = ""
TimeHelper::$webroot = "/"
TimeHelper::$themeWeb = NULL
TimeHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
TimeHelper::$params = array
TimeHelper::$action = "all_news"
TimeHelper::$plugin = "profiles"
TimeHelper::$data = NULL
TimeHelper::$namedArgs = NULL
TimeHelper::$argSeparator = NULL
TimeHelper::$validationErrors = NULL
TimeHelper::$tags = array
TimeHelper::$__tainted = NULL
TimeHelper::$__cleaned = NULL
TimeHelper::$_log = NULL
$form	=	FormHelper
FormHelper::$helpers = array
FormHelper::$fieldset = array
FormHelper::$__options = array
FormHelper::$fields = array
FormHelper::$requestType = NULL
FormHelper::$base = ""
FormHelper::$webroot = "/"
FormHelper::$themeWeb = NULL
FormHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
FormHelper::$params = array
FormHelper::$action = "all_news"
FormHelper::$plugin = "profiles"
FormHelper::$data = NULL
FormHelper::$namedArgs = NULL
FormHelper::$argSeparator = NULL
FormHelper::$validationErrors = NULL
FormHelper::$tags = array
FormHelper::$__tainted = NULL
FormHelper::$__cleaned = NULL
FormHelper::$_log = NULL
FormHelper::$Html = HtmlHelper object
$pai	=	PaiHelper
PaiHelper::$helpers = array
PaiHelper::$base = ""
PaiHelper::$webroot = "/"
PaiHelper::$themeWeb = NULL
PaiHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaiHelper::$params = array
PaiHelper::$action = "all_news"
PaiHelper::$plugin = "profiles"
PaiHelper::$data = NULL
PaiHelper::$namedArgs = NULL
PaiHelper::$argSeparator = NULL
PaiHelper::$validationErrors = NULL
PaiHelper::$tags = array
PaiHelper::$__tainted = NULL
PaiHelper::$__cleaned = NULL
PaiHelper::$_log = NULL
PaiHelper::$Html = HtmlHelper object
PaiHelper::$Form = FormHelper object
PaiHelper::$Session = SessionHelper object
$session	=	SessionHelper
SessionHelper::$helpers = NULL
SessionHelper::$__active = true
SessionHelper::$valid = false
SessionHelper::$error = false
SessionHelper::$_userAgent = "1f2fc9be373728e645f0927cf473d35d"
SessionHelper::$path = "/"
SessionHelper::$lastError = NULL
SessionHelper::$security = "medium"
SessionHelper::$time = 1337187010
SessionHelper::$sessionTime = 1337211010
SessionHelper::$watchKeys = array
SessionHelper::$id = NULL
SessionHelper::$_log = NULL
SessionHelper::$base = ""
SessionHelper::$webroot = "/"
SessionHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
SessionHelper::$params = array
SessionHelper::$action = "all_news"
SessionHelper::$data = NULL
SessionHelper::$themeWeb = NULL
SessionHelper::$plugin = "profiles"
$profile	=	ProfileHelper
ProfileHelper::$helpers = array
ProfileHelper::$base = ""
ProfileHelper::$webroot = "/"
ProfileHelper::$themeWeb = NULL
ProfileHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
ProfileHelper::$params = array
ProfileHelper::$action = "all_news"
ProfileHelper::$plugin = "profiles"
ProfileHelper::$data = NULL
ProfileHelper::$namedArgs = NULL
ProfileHelper::$argSeparator = NULL
ProfileHelper::$validationErrors = NULL
ProfileHelper::$tags = array
ProfileHelper::$__tainted = NULL
ProfileHelper::$__cleaned = NULL
ProfileHelper::$_log = NULL
ProfileHelper::$Html = HtmlHelper object
ProfileHelper::$Paginator = PaginatorHelper object
ProfileHelper::$Pai = PaiHelper object
$paginator	=	PaginatorHelper
PaginatorHelper::$helpers = array
PaginatorHelper::$__defaultModel = NULL
PaginatorHelper::$options = array
PaginatorHelper::$base = ""
PaginatorHelper::$webroot = "/"
PaginatorHelper::$themeWeb = NULL
PaginatorHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
PaginatorHelper::$params = array
PaginatorHelper::$action = "all_news"
PaginatorHelper::$plugin = "profiles"
PaginatorHelper::$data = NULL
PaginatorHelper::$namedArgs = NULL
PaginatorHelper::$argSeparator = NULL
PaginatorHelper::$validationErrors = NULL
PaginatorHelper::$tags = array
PaginatorHelper::$__tainted = NULL
PaginatorHelper::$__cleaned = NULL
PaginatorHelper::$_log = NULL
PaginatorHelper::$Html = HtmlHelper object
PaginatorHelper::$Ajax = AjaxHelper object
$ajax	=	AjaxHelper
AjaxHelper::$helpers = array
AjaxHelper::$Html = HtmlHelper object
AjaxHelper::$Javascript = JavascriptHelper object
AjaxHelper::$callbacks = array
AjaxHelper::$ajaxOptions = array
AjaxHelper::$dragOptions = array
AjaxHelper::$dropOptions = array
AjaxHelper::$sortOptions = array
AjaxHelper::$sliderOptions = array
AjaxHelper::$editorOptions = array
AjaxHelper::$autoCompleteOptions = array
AjaxHelper::$__ajaxBuffer = array
AjaxHelper::$base = ""
AjaxHelper::$webroot = "/"
AjaxHelper::$themeWeb = NULL
AjaxHelper::$here = "/LON:AMP/Amphion-Innovations/all_news"
AjaxHelper::$params = array
AjaxHelper::$action = "all_news"
AjaxHelper::$plugin = "profiles"
AjaxHelper::$data = NULL
AjaxHelper::$namedArgs = NULL
AjaxHelper::$argSeparator = NULL
AjaxHelper::$validationErrors = NULL
AjaxHelper::$tags = array
AjaxHelper::$__tainted = NULL
AjaxHelper::$__cleaned = NULL
AjaxHelper::$_log = NULL
AjaxHelper::$Form = FormHelper object</pre><pre>header - [internal], line ??
include - APP/views/layouts/rss.ctp, line 4
View::_render() - CORE/cake/libs/view/view.php, line 667
View::renderLayout() - CORE/cake/libs/view/view.php, line 454
View::render() - CORE/cake/libs/view/view.php, line 388
Controller::render() - CORE/cake/libs/controller/controller.php, line 806
Dispatcher::_invoke() - CORE/cake/dispatcher.php, line 230
Dispatcher::dispatch() - CORE/cake/dispatcher.php, line 194
[main] - APP/webroot/index.php, line 91</pre></div><?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
	<title>Proactiveinvestors United Kingdom Amphion Innovations</title>
	<link>http://www.proactiveinvestors.co.uk</link>
	<description>Proactiveinvestors United Kingdom Amphion Innovations RSS feed
            </description>
	<language>en</language>
	<pubDate>Wed, 16 May 2012 17:50:10 +0100</pubDate>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<generator>Genera CMS</generator>
	<managingEditor>action@proactiveinvestors.com (Proactiveinvestors)</managingEditor>
	<webMaster>action@proactiveinvestors.com (Proactiveinvestors)</webMaster>
	<atom:link href="http://www.proactiveinvestors.co.uk/LON:AMP/Amphion-Innovations/all_news" rel="self" type="application/rss+xml" />
		<item>
			<title><![CDATA[News - Amphion Innovations gets US$500,000 loan from chairman ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html</link>
			<description><![CDATA[<p>
<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>), which develops medical and technology businesses, told investors today it had secured further loan financing from its chairman James Macaleer.</p>
<p>The company has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.43 per cent stake in the company, it said in a stock exchange statement.</p>
<p>The loan is repayable on November 4 this year, and carries interest at 7 per cent per year.</p>
<p>On May 1 this year, the company revealed that a Markman ruling was issued in a Texas patent case involving Axcess International - one of Amphion&rsquo;s partner companies.</p>
<p>A Markman is a pre-trial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&nbsp;</p>
<p>It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.</p>
<p>Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.</p>
<p>The judge essentially upheld the validity of Axcess&rsquo; claim and set down the case for trial on November 5.</p>
<p>Amphion described the ruling can as &ldquo;favourable&rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial.&nbsp;</p>
</p> ]]></description>
			<pubDate>Wed, 09 May 2012 09:36:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/42532/amphion-innovations-gets-us500000-loan-from-chairman-42532.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Funding update ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/</link>
			<description><![CDATA[]]></description>
			<pubDate>Wed, 09 May 2012 09:20:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120509amp9601c/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations’ partner Axcess reaches milestone in patent case ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html</link>
			<description><![CDATA[<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>) said a Markman ruling was issued in a Texas patent case involving Axcess International, one of Amphion&rsquo;s partner companies.</p>
<p>A Markman is a pretrial hearing in the US District Court, in this instance the Northern District of Texas, Dallas Division.&nbsp;</p>
<p>It is held so a judge can examine evidence from both sides on the appropriate meanings of relevant key words used in a patent claim.</p>
<p>Axcess is alleging that a firm called Savi Technology infringed its patent on a method of improving the range and sensitivity of radio tags.</p>
<p>The judge essentially upheld the validity of Axcess&rsquo; claim and set down the case for trial on November 5.</p>
<p>Amphion described the ruling can as &ldquo;favourable&rdquo;, though it cautioned that this does not automatically mean that Axcess will win at trial. &nbsp;</p>
<p>Axcess chief executive Allan Griebenow said: "Having reached this important milestone, we now look forward to the trial in early November. &nbsp;We encourage interested parties to read the order.</p>
<p>&ldquo;Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio."</p>
<p>Amphion owns 14 per cent of Axcess and holds US$1.8 million of debt.</p>
<p>A copy of the court's ruling can be downloaded from <a href="http://www.proactiveinvestors.co.uk/www.axcessinc.com" target="_blank">www.axcessinc.com</a>.</p> ]]></description>
			<pubDate>Tue, 01 May 2012 08:20:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/42192/amphion-innovations-partner-axcess-reaches-milestone-in-patent-case-42192.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Partner Company Update ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/</link>
			<description><![CDATA[]]></description>
			<pubDate>Tue, 01 May 2012 07:00:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120501amp4213c/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations partner Axcess secures up to US$10 mln credit facility ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html</link>
			<description><![CDATA[<p>Technology commercialisation firm <a href="http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>) said its partner company Axcess International Inc, a provider of intelligent Wireless IDs, has secured a credit facility of up to US$10 million with RFID LLC.<br /><br />The immediate credit facility totals US$1.48 million and under circumstances related primarily to the intellectual property litigation activities, a total of US$10 million could be made available.</p>
<p>Axcess has a portfolio of patents, of which 11 have been issued and 2 are still subject to litigation against a Lockheed Martin Corp subsidiary.<br /><br />Axcess filed a lawsuit in May 2010 against Savi Technology Inc alleging infringement of 2 US Patents, one titled "High Sensitivity Demodulator For A Radio Tag And Method" and the other "Dual Frequency Radio Tag For A Radio Frequency Identification System".&nbsp; <br /><br />The trial is set for the first quarter of 2013 and hearing is scheduled for April 9 2012.<br /><br />The credit agreement provides for the funding of a patent licensing programme to begin in 2012 designed to provide additional revenue to the company based on the 11 patents in its portfolio.&nbsp; <br /><br />The agreement further provides the potential to restructure short-term debt, pay accrued legal bills related to the various patent litigation activities, and to provide funding for overhead and administrative operations.&nbsp; <br /><br />The returns to the investors participating in the credit agreement will, in most circumstances, accrue mainly from the patent litigation and patent licensing programmes. <br /><br />Axcess chief executive Allan Griebenow said: &ldquo;This credit facility is an important step in the prosecution of our current infringement actions with Savi, which we believe will create potential licensing opportunities and a financial platform in support of our continuing operations."<br />&nbsp;<br />Amphion has a 13.8 per cent stake in Axcess, which excludes approximately US$1.8 million in debt, most of which is convertible into common stock.</p> ]]></description>
			<pubDate>Wed, 28 Mar 2012 08:19:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/40829/amphion-innovations-partner-axcess-secures-up-to-us10-mln-credit-facility-40829.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Partner Company Update ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/</link>
			<description><![CDATA[]]></description>
			<pubDate>Wed, 28 Mar 2012 07:00:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120328amp2148a/</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Director Dealings ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/</link>
			<description><![CDATA[]]></description>
			<pubDate>Tue, 28 Feb 2012 07:01:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120228amp2246y/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations secures additional US$500,000 loan from chairman ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html</link>
			<description><![CDATA[<p><a href="http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>)), the developer of medical and technology businesses, told investors it had secured further loan financing from its chairman James Macaleer.<br /><br />It has secured additional unsecured loan financing of US$500,000 from Macaleer, who is interested in 17.37 per cent stake in the company, it said in a statement.<br /><br />The loan is repayable on August 21 this year, and carries interest at 7 per cent per year.<br /><br />Macaleer will also receive 500,000 warrants expiring on December 31, 2013, each entitling the holder to subscribe for one share at 8 pence.<br /><br />Earlier this month - on February 3 - Amphion announced it had secured an additional loan of US$500,000 from the chairman, repayable on December 31, 2013 with interest at 7 per cent per annum.</p> ]]></description>
			<pubDate>Fri, 24 Feb 2012 07:15:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/39373/amphion-innovations-secures-additional-us500000-loan-from-chairman-39373.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Funding Update ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/</link>
			<description><![CDATA[]]></description>
			<pubDate>Thu, 23 Feb 2012 16:37:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120223amp0271y/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations secures US$500,000 loan from chairman ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html</link>
			<description><![CDATA[<p><a href="http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>), the developer of medical and technology businesses, said it has secured additional unsecured loan financing of US$500,000 from its chairman James Macaleer.<br /><br />Macaleer holds a 17.37 per cent stake in the company.<br /><br />The loan is repayable on December 31 2013 and carries interest at 7 per cent per annum.<br /><br />The chairman&rsquo;s unsecured loan financing to Amphion now totals US$4 million, all with the same maturity and interest.<br /><br />Macaleer will also receive 2 million warrants, expiring on December 2013, each entitling the holder to subscribe for one Amphion share at 8 pence. <br /><br />This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company's nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.</p> ]]></description>
			<pubDate>Fri, 03 Feb 2012 15:52:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/38573/amphion-innovations-secures-us500000-loan-from-chairman-38573.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Funding Update ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/</link>
			<description><![CDATA[]]></description>
			<pubDate>Fri, 03 Feb 2012 15:24:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120203amp7979w/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations shares rise as DataTern patents are reinforced ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html</link>
			<description><![CDATA[<p>The group has been working to reinforce its IP position in recent years. Today it revealed that 20 of its original claims can be patented following re-examinations by the&nbsp;United States Patent and Trademark Office.</p>]]></description>
			<pubDate>Thu, 02 Feb 2012 10:39:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/38505/amphion-innovations-shares-rise-as-datatern-patents-are-reinforced-38505.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Patent Approval ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/</link>
			<description><![CDATA[]]></description>
			<pubDate>Thu, 02 Feb 2012 07:00:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/120202amp6339w/</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Director Dealings ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/</link>
			<description><![CDATA[]]></description>
			<pubDate>Fri, 30 Dec 2011 07:00:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/111230amp7695u/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations is significantly undervalued against its NAV, says broker ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html</link>
			<description><![CDATA[<p>Technology commercialisation firm <a href="http://proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.<br /><br />The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a 'buy' targeting a price of 10 pence (current price: 4 pence a share).<br /><br />"In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV," said Mitchell.<br /><br />However, the analyst conceded that in the light of wider market conditions, that discount was justified.<br /><br />But he added: "However, with the DataTern business effectively acting as an &lsquo;engine&rsquo; for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone. <br /><br />"Instead, we believe a discount of around 30 per cent is more justified," he said, adding that the broker's own target price had been worked out at 10 pence.<br /><br />Since floating in 2005, the firm's strategy has been to build high-potential companies with innovative, proprietary, and proven technology. <br /><br />This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.<br /><br />"While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues," said Dr Mitchell.<br /><br />The analyst added that DataTern's ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.<br /><br />"Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.<br /><br />"We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term," concluded the analyst.</p> ]]></description>
			<pubDate>Mon, 19 Dec 2011 13:40:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/37123/amphion-innovations-is-significantly-undervalued-against-its-nav-says-broker-37123.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Director/PDMR Shareholding ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/</link>
			<description><![CDATA[]]></description>
			<pubDate>Tue, 06 Dec 2011 09:10:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/111206amp4225t/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations subsidiary DataTern files patent infringement suits in US  ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html</link>
			<description><![CDATA[<p>Technology commercialisation firm <a href="http://www.proactiveinvestors.co.uk/companies/overview/89/Amphion+Innovations" class="companyPopupTrigger" rel="89">Amphion Innovations</a> (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html" class="companyPopupTrigger" rel="89">LON:AMP</a>) said its subsidiary DataTern Inc has filed patent infringement cases against a number of companies in the US.<br /><br />The suits were filed in the District Court of Massachusetts, asserting infringement of the '502 patent.&nbsp; <br /><br />The '502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases.&nbsp; As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products, Amphion said. <br /><br />DataTern chief executive officer John Caruso said: "Numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology.&nbsp; We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission."<br /><br />DataTern fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors.&nbsp;&nbsp; DataTern is represented by McCarter &amp; English LLP in Boston.<br /><br />Amphion also announced today that it has agreed additional unsecured loan financing of US$500,000 from its chairman R James Macaleer, who is also interested in 17.31 percent of the issued share capital.&nbsp; <br /><br />The loan is repayable on February 15 2012 and carries an interest rate of 7 percent per annum.&nbsp; <br /><br />Furthermore, as part of the new debt facility agreement, outstanding loans to Macaleer as announced on April 15 2011 and December 9 2010 which became payable on January 31 2012 for a total of US$1 million have been extended until December 31 2012, and a loan of US$2 million which became payable on December 31 2012 has been extended to December 31 2013. All loans will carry the interest rate of 7 percent per annum.<br /><br />Interim results from Amphion reported at the end of Septenber showed that the firm moved into the black during the first six months of the year on increased revenues.<br /><br />The firm&rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &pound;270,403 (H1 2010: &pound;2.7 million).</p> ]]></description>
			<pubDate>Mon, 21 Nov 2011 10:18:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/35883/amphion-innovations-subsidiary-datatern-files-patent-infringement-suits-in-us--35883.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - New Suits Filed and New Debt Facilites ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/</link>
			<description><![CDATA[]]></description>
			<pubDate>Mon, 21 Nov 2011 08:43:00 +0000</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/111121amp4373s/</guid>
		</item>
		<item>
			<title><![CDATA[News - Amphion Innovations moves into the black during first half ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html</link>
			<description><![CDATA[<p>&nbsp;</p>
<p>Interim results from Amphion Innovations (<a href="http://www.proactiveinvestors.co.uk/companies/overview/89/amphion-innovations-0089.html"><a href="/companies/overview/89/amphion-innovations-0089.html">LON:AMP</a></a>) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.</p>
<p>The firm&rsquo;s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of &pound;270,403 (H1 2010: &pound;2.7 million).</p>
<p>Amphion&rsquo;s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter &amp; English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark. &nbsp;DataTern has taken &ldquo;concrete steps&rdquo; to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.</p>
<p>Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business&rsquo;s &lsquo;402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern&rsquo;s confidence in the validity of the patent justifies exposing it to re-examination.</p>
<p>DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).</p>
<p>Among Amphion&rsquo;s &lsquo;Partner Companies&rsquo; Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an &ldquo;important and exciting&rdquo; partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.</p>
<p>&ldquo;We are pleased to be reporting an improved set of results for the company,&rdquo; said Richard Morgan, Amphion&rsquo;s chairman and chief executive officer. &ldquo;Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially. &nbsp;Improved performance by DataTern should in due course lead to an improvement in Amphion's results, with a positive impact on Amphion's financial condition and its ability to fund and grow its Partner Companies.&rdquo;</p>
<p>&nbsp;</p>]]></description>
			<pubDate>Thu, 29 Sep 2011 07:43:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/news/33728/amphion-innovations-moves-into-the-black-during-first-half-33728.html</guid>
		</item>
		<item>
			<title><![CDATA[RNS press release - Half Yearly Report ]]></title>
			<link>http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/</link>
			<description><![CDATA[]]></description>
			<pubDate>Thu, 29 Sep 2011 07:00:00 +0100</pubDate>
			<guid>http://www.proactiveinvestors.co.uk/companies/rns/110929amp1345p/</guid>
		</item>
</channel>
</rss>